A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

Ipilimumab (IPI) can enhance immunity to the cancer-testis antigen NY-ESO-1. A clinical trial was designed to assess safety, immunogenicity, and clinical responses with IPI + NY-ESO-1 vaccines and effects on the tumor microenvironment (TME). Patients with measurable NY-ESO-1(+) tumors were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Slingluff, Craig L., Zarour, Hassane M., Tawbi, Hussein Abdul-Hassan, Kirkwood, John M., Postow, Michael A., Friedlander, Philip, Devoe, Craig E., Gaughan, Elizabeth M., Mauldin, Ileana S., Olson, Walter C., Smith, Kelly T., Macri, Mary J., Ricciardi, Toni, Ryan, Aileen, Venhaus, Ralph, Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007150/
https://www.ncbi.nlm.nih.gov/pubmed/33796406
http://dx.doi.org/10.1080/2162402X.2021.1898105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007150/
https://www.ncbi.nlm.nih.gov/pubmed/33796406
http://dx.doi.org/10.1080/2162402X.2021.1898105

Ejemplares similares